Evidence map›Paper›PMID 42527617›Full record

ArticleCardiovascular and interventional radiology2026

High-Specific-Activity Resin Yttrium-90 Radiation Segmentectomy of Hepatocellular Carcinoma: A Study of Efficacy, Safety, and Dosimetry Considerations.

Alexander Villalobos, Ali Alfrasiabi, Paolo Varela, Roshan Valentine, Bahareh Gholami, Haneyeh Shahbazian, Andrew M Moon, Neil Shah, Johannes L Du Pisanie, Hyeon Yu and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Alexander VillalobosDivision of Vascular and Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, 101 Manning Drive, Chapel Hill, NC, 27514, USA. A.Villalobos@unc.edu.ORCID http://orcid.org/0000-0002-8920-7459
Ali AlfrasiabiDivision of Vascular and Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, 101 Manning Drive, Chapel Hill, NC, 27514, USA.
Paolo VarelaDivision of Vascular and Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, 101 Manning Drive, Chapel Hill, NC, 27514, USA.
Roshan ValentineDivision of Vascular and Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, 101 Manning Drive, Chapel Hill, NC, 27514, USA.
Bahareh GholamiDivision of Vascular and Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, 101 Manning Drive, Chapel Hill, NC, 27514, USA.
Haneyeh ShahbazianDivision of Vascular and Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, 101 Manning Drive, Chapel Hill, NC, 27514, USA.
Andrew M MoonDivision of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27514, USA.
Neil ShahDivision of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27514, USA.
Johannes L Du PisanieDivision of Vascular and Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, 101 Manning Drive, Chapel Hill, NC, 27514, USA.
Hyeon YuDivision of Vascular and Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, 101 Manning Drive, Chapel Hill, NC, 27514, USA.
David M MauroDivision of Vascular and Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, 101 Manning Drive, Chapel Hill, NC, 27514, USA.
Nima KokabiDivision of Vascular and Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, 101 Manning Drive, Chapel Hill, NC, 27514, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate efficacy, safety, particle density, and dosimetry of high-specific-activity (HSA) resin-based (RB) Yttrium-90 radiation segmentectomy (Y90-RS) for hepatocellular carcinoma (HCC). MATERIALS AND

methodsAll 4- and 5-day pre-calibration (DPC) Y90-RS performed on patients with HCC were retrospectively analyzed at a single-center between July 2023 and May 2025. Tumor response and adverse events (AE) were assessed using mRECIST and CTCAE v5 at 3, 6, and 12-months. Voxel-based dosimetry analysis on post-Y90 SPECT/CT was performed to create tumor dose (TD) volume histograms and particle density (PD) assessment. Receiver Operating Characteristic (ROC) curves were used to evaluate the dose thresholds able to predict a tumor complete response (CR) in relation to TD and PD. Variable differences were assessed with a Mann-Whitney U Test and the Chi-Square tests.

resultsSixty patients (63 tumors) underwent HSA RB Y90-RS (62% 4-DPC). The cohort was 62% male, median age 66 years (IQR, 62-71), with 95% solitary HCC. At 3 months, tumor control was 100% and CR was 79%. Treatment was well tolerated, with only two patients developing grade 3 AEs. The median delivered mean TD was 423 Gy (IQR 316-712), with the CR cohort showing higher mean TD than the incomplete response cohort (546 Gy vs. 299 Gy; p = 0.0003). Tumor PD and Mean TD thresholds predicting 3-month CR were 45,494 microspheres/mL (AUC = 0.80) and 416 Gy (AUC = 0.83), respectively. D95 TD of > 245 Gy was associated with CR (AUC = 0.81).

conclusionCurative intent ablative Y90-RS of HCC with HSA RB microspheres is efficacious and well tolerated. Mean TD threshold of ≥ 416 Gy and tumor-PD of ≥ 45,494 microspheres/mL were associated with 3-month tumor CR.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsYttrium RadioisotopesAgedFemaleHumansMaleMiddle AgedRadioembolization, TherapeuticRadiotherapy DosageRetrospective StudiesSingle Photon Emission Computed Tomography Computed TomographyTreatment OutcomeYttrium-90Yttrium RadioisotopesHepatocellular carcinomaLocoregional therapyRadiation segmentectomyResin-based yttrium-90Transarterial radioembolization

Identifiers

PMID42527617

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.